IL-17 expression in human herpetic stromal keratitis: modulatory effects on chemokine production by corneal fibroblasts.
Herpetic stromal keratitis (HSK) is an immunopathologic disease triggered by infection of the cornea with HSV. Key events in HSK involve the interaction between cornea-infiltrating inflammatory cells and resident cells. This interaction, in which macrophages, producing IL-1 and TNF-alpha, and IFN-gamma-producing Th1 cells play a crucial role, results in the local secretion of immune-modulatory factors and a major influx of neutrophils causing corneal lesions and blindness. The Th1-derived cytokine IL-17 has been shown to play an important role in several inflammatory diseases characterized by a massive infiltration of neutrophils into inflamed tissue. Here we show that IL-17 is expressed in corneas from patients with HSK and that the IL-17R is constitutively expressed by human corneal fibroblasts (HCF). IL-17 exhibited a strong synergistic effect with TNF-alpha on the induction of IL-6 and IL-8 secretion by cultured HCF. Secreted IL-8 in these cultures had a strong chemotactic effect on neutrophils. IL-17 also enhanced TNF-alpha- and IFN-gamma-induced secretion of macrophage-inflammatory proteins 1alpha and 3alpha, while inhibiting the induced secretion of RANTES. Furthermore, considerable levels of IFN-gamma-inducible protein 10 and matrix metalloproteinase 1 were measured in stimulated HCF cultures, while the constitutive secretion of monocyte chemotactic protein 1 remained unaffected. The data presented suggest that IL-17 may play an important role in the induction and/or perpetuation of the immunopathologic processes in human HSK by modulating the secretion of proinflammatory and neutrophil chemotactic factors by corneal resident fibroblasts.
Maertzdorf
Jeroen
J
Institute of Virology, Erasmus Medical Center, Dr. Molewaterplein 50, 3015 GE Rotterdam, The Netherlands.
Osterhaus
Albert D M E
AD
Verjans
Georges M G M
GM
D000276:Adjuvants, Immunologic / Q000096:biosynthesis* / Q000378:metabolism / Q000494:pharmacology / Q000502:physiology; D002460:Cell Line; D002478:Cells, Cultured; D018925:Chemokines / Q000096:biosynthesis* / Q000378:metabolism; D003315:Cornea / Q000276:immunology* / Q000378:metabolism* / Q000473:pathology; D004357:Drug Synergism; D005347:Fibroblasts / Q000201:enzymology / Q000276:immunology* / Q000378:metabolism*; D006801:Humans; D020381:Interleukin-17 / Q000096:biosynthesis* / Q000378:metabolism / Q000494:pharmacology / Q000502:physiology; D015850:Interleukin-6 / Q000378:metabolism; D016209:Interleukin-8 / Q000378:metabolism / Q000502:physiology; D016849:Keratitis, Herpetic / Q000276:immunology* / Q000473:pathology; D020781:Matrix Metalloproteinase 1 / Q000378:metabolism; D020556:Neutrophil Infiltration / Q000276:immunology; D018123:Receptors, Interleukin / Q000096:biosynthesis; D053722:Receptors, Interleukin-17; D011994:Recombinant Proteins / Q000096:biosynthesis; D017154:Stromal Cells / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D016176:T-Lymphocyte Subsets / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology
D000276:Adjuvants, Immunologic; D018925:Chemokines; C109985:IL17RA protein, human; D020381:Interleukin-17; D015850:Interleukin-6; D016209:Interleukin-8; D018123:Receptors, Interleukin; D053722:Receptors, Interleukin-17; D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha; D020781:Matrix Metalloproteinase 1